title: Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.
authors.affiliation: *Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), INSERM, Sorbonne Universités, UPMC Univ Paris 06, Paris, France †Department of Virology, Hôpital Saint-Antoine, APHP, Paris, France ‡Department of Virology, Hôpital Pitié-Salpêtrière, APHP, Paris, France §Department of Infectious Diseases, Hôpital Saint-Antoine, APHP, Paris, France Sorbonne University, UPMC Univ Paris 06 CR7, INSERM U1135, CIMI, Team E13, Paris, France.
authors.forename: Eve
authors.initials: E
authors.lastname: Todesco
authors.forename: Laure
authors.initials: L
authors.lastname: Surgers
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Meynard
authors.forename: Laurence
authors.initials: L
authors.lastname: Morand-Joubert
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics*; D000068679:Emtricitabine / Q000627:therapeutic use*; D060005:Genotyping Techniques; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D012194:RNA-Directed DNA Polymerase / Q000235:genetics / Q000378:metabolism; D000068696:Rilpivirine / Q000627:therapeutic use*; D000068698:Tenofovir / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D000068698:Tenofovir; D012194:RNA-Directed DNA Polymerase; D000068696:Rilpivirine; D000068679:Emtricitabine